Development of cyclic peptides that can be administered orally to inhibit disease targets
Cyclic peptides can bind challenging disease targets, but their oral application is hindered by digestion and absorption issues. We developed a versatile method for the synthesis and functional screening of vast numbers of synthetic cyclic peptides and identified peptides with high inhibitory activity, stability and oral bioavailability in rats.
Cite this item
Merz, M. L., & Heinis, C. (2023). Development of cyclic peptides that can be administered orally to inhibit disease targets. Nature Chemical Biology. https://doi.org/10.1038/s41589-023-01505-0
Click Copy to copy the citation, or select the text manually.
Merz_Heinis_Nat_Chem_Biol_2023_Briefing.pdf
Publisher
Published version
openaccess
CC BY
989.83 KB
Adobe PDF
4c7d2612a4916fb756c614ba0929ccb9